Grant: A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM
| Project Title |
A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM
|
|---|---|
| Principal Investigator | Ho, James Chung Man (Principal investigator) |
| Co-Investigator(s) |
Lam, Chi Leung David
(Co-Investigator)
Dr Wong Matthew (Co-Investigator) Dr Lam Jamie (Co-Investigator) |
| Funding Year |
2011/2012
|
| Amount |
207773
|
| Panel | Medicine |
| Start Date |
01-02-2012
|
| Expected Completion |
31-01-2015
|
| Status |
On-going
|
| Keywords | Non-small cell lung cancer |
| Grant Type/Funding Scheme | Pharmaceutical Industry - General Award |
| Duration |
36
|
[Coming Soon]